Barclays’s Genmab GMAB Stock Holding History

Barclays’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$143K	Buy	+4,000	New	+$127K	﹤0.01%	4160

Other funds holding GMAB

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.4B AUM 32.2% 1-Year Est. Return

Oppenheimer Asset Management New York $9.5B AUM 23.46% 1-Year Est. Return

Eagle Global Advisors Houston, Texas $3.02B AUM 27.86% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

IMC Chicago Chicago, Illinois $483B AUM 41.26% 1-Year Est. Return

Barclays's GMAB Position: Q3 2026 in Review

Barclays increased its Genmab (GMAB) stake by 6,536% in Q3 2026, buying an estimated $331K and bringing the position to 10,617 shares worth $379K. The position accounts for ﹤0.01% of the portfolio, ranked #3614.

Barclays first reported a position in GMAB in Q3 2019 and has held it in 27 quarters since. The position peaked at $1.82M in Q1 2024. 166 funds tracked by Wall St. Rank hold GMAB as of Q3 2026.

Barclays held 10,617 shares of Genmab worth $379K as of Q3 2026.
Barclays bought 10,457 Genmab shares in Q3 2026, an estimated $331K.
Genmab made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3614 holding.
Barclays first reported a position in Genmab in Q3 2019 and has held it in 27 quarters since.
Barclays's Genmab position peaked at $1.82M in Q1 2024.
166 funds tracked by Wall St. Rank held Genmab as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.